ADMA Biologics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on June 2, 2026. The Company, incorporated in Delaware, is listed on the Nasdaq Global Market under the symbol ADMA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to stockholders and approved:
- Proposal 1 (Election of Class I Directors): Two nominees were elected to serve until the 2029 Annual Meeting.
- Alison C. Finger: 156,849,830 votes For; 19,376,842 votes Withheld.
- Eduardo Rene Salas: 171,947,523 votes For; 4,279,149 votes Withheld.
- Proposal 2 (Ratification of Auditors): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 198,655,040 votes For; 329,056 votes Against; 283,451 votes Abstain.
- Proposal 3 (Say-on-Pay): The non-binding advisory approval of named executive officer compensation was approved.
- 168,169,866 votes For; 7,730,690 votes Against; 326,116 votes Abstain.
Quorum and Participation: As of the record date (April 8, 2026), 232,324,283 shares were outstanding. 199,267,547 shares were represented at the meeting, constituting a quorum.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Class I directors' tenure ending in 2029.
- Verification of KPMG LLP's engagement for the 2026 fiscal year audit.
- Review of the specific executive compensation details referenced in the approved Say-on-Pay proposal.
- Analysis of the significant number of broker non-votes (23,040,875) on director and Say-on-Pay proposals.